A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 187,849 shares of AKBA stock, worth $345,642. This represents 0.0% of its overall portfolio holdings.

Number of Shares
187,849
Previous 151,849 23.71%
Holding current value
$345,642
Previous $154,000 60.39%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.94 - $1.55 $33,840 - $55,800
36,000 Added 23.71%
187,849 $247,000
Q2 2024

Aug 14, 2024

SELL
$0.86 - $1.63 $6,966 - $13,203
-8,100 Reduced 5.06%
151,849 $154,000
Q1 2024

May 15, 2024

SELL
$1.27 - $2.24 $8,890 - $15,680
-7,000 Reduced 4.19%
159,949 $292,000
Q4 2023

Feb 14, 2024

SELL
$0.8 - $1.28 $5,200 - $8,320
-6,500 Reduced 3.75%
166,949 $207,000
Q3 2023

Nov 14, 2023

BUY
$0.87 - $1.84 $2,697 - $5,704
3,100 Added 1.82%
173,449 $197,000
Q2 2023

Aug 14, 2023

SELL
$0.51 - $1.43 $24,480 - $68,640
-48,000 Reduced 21.98%
170,349 $156,000
Q1 2023

May 15, 2023

BUY
$0.56 - $1.15 $672 - $1,380
1,200 Added 0.55%
218,349 $122,000
Q4 2022

Feb 14, 2023

BUY
$0.25 - $0.58 $300 - $696
1,200 Added 0.56%
217,149 $125,000
Q3 2022

Nov 14, 2022

SELL
$0.3 - $0.46 $7,620 - $11,684
-25,400 Reduced 10.52%
215,949 $68,000
Q2 2022

Aug 15, 2022

SELL
$0.32 - $0.67 $31,392 - $65,727
-98,100 Reduced 28.9%
241,349 $85,000
Q1 2022

May 16, 2022

SELL
$0.72 - $2.93 $44,064 - $179,316
-61,200 Reduced 15.28%
339,449 $244,000
Q4 2021

Feb 14, 2022

BUY
$2.26 - $3.34 $85,330 - $126,108
37,757 Added 10.4%
400,649 $905,000
Q3 2021

Nov 15, 2021

BUY
$2.35 - $3.88 $8,225 - $13,580
3,500 Added 0.97%
362,892 $1.05 Million
Q2 2021

Aug 16, 2021

SELL
$2.83 - $4.2 $1.73 Million - $2.56 Million
-609,753 Reduced 62.92%
359,392 $1.36 Million
Q1 2021

May 17, 2021

BUY
$2.92 - $5.06 $1.79 Million - $3.11 Million
614,617 Added 173.36%
969,145 $3.28 Million
Q4 2020

Feb 16, 2021

SELL
$2.22 - $3.78 $80,070 - $136,337
-36,068 Reduced 9.23%
354,528 $993,000
Q3 2020

Nov 16, 2020

BUY
$2.39 - $13.08 $473,208 - $2.59 Million
197,995 Added 102.8%
390,596 $980,000
Q2 2020

Aug 14, 2020

BUY
$6.67 - $13.58 $1.1 Million - $2.24 Million
164,995 Added 597.68%
192,601 $2.62 Million
Q1 2020

May 15, 2020

BUY
$4.1 - $10.24 $113,184 - $282,685
27,606 New
27,606 $209,000
Q3 2018

Nov 14, 2018

SELL
$7.44 - $10.65 $360,096 - $515,460
-48,400 Closed
0 $0
Q2 2018

Aug 14, 2018

SELL
$9.15 - $11.34 $313,845 - $388,962
-34,300 Reduced 41.48%
48,400 $483,000
Q1 2018

May 15, 2018

SELL
$9.53 - $15.68 $15,247 - $25,088
-1,600 Reduced 1.9%
82,700 $788,000
Q4 2017

Feb 14, 2018

BUY
$14.24 - $19.59 $82,592 - $113,622
5,800 Added 7.39%
84,300 $1.25 Million
Q3 2017

Nov 14, 2017

BUY
$13.06 - $19.67 $1.03 Million - $1.54 Million
78,500
78,500 $1.54 Million

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $338M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.